Terray Therapeutics, a biotechnology company revolutionizing small molecule drug development, has secured $120 million in Series B funding. This latest investment brings the company’s total equity financing since its inception to over $200 million. The funding will propel Terray’s internal programs into clinical trials and further bolster its integrated AI platform, tNova. This platform is instrumental in driving both internal drug discovery programs and collaborations with partners.
Bedford Ridge Capital spearheaded the funding round, joined by existing investor NVentures (NVIDIA’s venture capital arm). Other participants include Maverick Capital, Goldcrest Capital, Madrona Ventures, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, and Alexandria Ventures. As part of the investment, Sid Shenai, representing Bedford Ridge Capital, will join Terray’s Board of Directors.
Terray distinguishes itself through its proprietary experimental platform, enabling the creation of the world’s most extensive chemistry dataset. With over 5 billion target-ligand interactions measured in just three years, this dataset dwarfs all publicly available chemistry data combined. Growing exponentially, it fuels Terray’s cutting-edge AI capabilities, enabling the discovery and optimization of novel small molecule solutions for complex therapeutic challenges. The company applies this expertise to its internal pipeline, which is focused on immunological diseases, and to challenging targets in partnerships with Bristol Myers Squibb and Calico.
Since its Series A funding in 2021, Terray has emerged as a frontrunner in AI-driven small-molecule drug design. Its success can be attributed to its innovative approach of combining high-throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. This unique platform positions Terray to address the most pressing therapeutic challenges and deliver on the potential of AI for small-molecule drug discovery.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
